EXACT Therapeutics

EXTX

NO0010852213

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
6.8 ^NOK	0.00%		-2.86%	-43.33%

Apr. 19	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

EXACT THERAPEUTICS AS - MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER

December 05, 2021 at 09:35 am EST

Oslo, 5 December 2021

Masha Strømme, chair of EXACT Therapeutics AS has on 2 December 2021 acquired 2
498  shares at an average price of NOK 16.0196 and on 3 December 2021 acquired 1
772 shares at an average price of NOK 17.1806, in EXACT Therapeutics AS. The
shares were acquired through PAACS Invest AS,  Dr. Strømme's investment company.
Following the transaction, Dr. Strømme controls 2 689 009 shares in EXACT
Therapeutics AS.

EXACT THERAPEUTICS AS - MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER
Oslo, 5 December 2021

Svein Kvåle, COO and Co-Founder of EXACT Therapeutics AS has on 2 December 2021
acquired 2 498  shares at an average price of NOK 16.0196 and on 3 December 2021
acquired 1 772 shares at an average price of NOK 17.1806, in EXACT Therapeutics
AS. The shares were acquired through Kvåle AS, a company controlled by Dr.
Kvåle. Following the transaction, Dr. Kvåle controls  3 021 770 shares in EXACT
Therapeutics AS.

EXACT THERAPEUTICS AS - MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER
Oslo, 5 December 2021

Andrew J. Healy, CSO and Co-Founder of EXACT Therapeutics AS has on 2 December
2021 acquired 1 249 shares at an average price of NOK 16.0196 and on 3 December
2021 acquired 886 shares at an average price of NOK 17.1806, in EXACT
Therapeutics AS. Following the transaction, Dr. Healy controls 2 205 385 shares
in EXACT Therapeutics AS.

Click here for more information

Latest news about EXACT Therapeutics

EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	23-10-31	MT
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
EXACT Therapeutics AS Announces Appointment of Caspar Foghsgaard as SVP Commercial & Business Development Effective 1 November 2023	23-09-27	CI
Exact Therapeutics Jumps 13% After Positive Outcomes From Acoustic Cluster Therapy Trial	23-09-26	MT
EXACT Therapeutics Announces Positive Clinical Results from the Activate Phase I Dose Escalation	23-09-25	CI
Exact Therapeutics, Cordance Medical to Collaborate on Drug Delivery Solutions for Brain Treatment	23-09-06	MT
EXACT Therapeutics and Cordance Medical Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain	23-09-05	CI
Exact Therapeutics Concludes Dose Escalation Under Cancer Therapy Study	23-08-07	MT
EXACT Therapeutics Completes the Dose Escalation Part of ACTIVATE Study	23-08-06	CI
EXACT Therapeutics AS Receives Regulatory Approval to Start the Dose Expansion Part of ACTIVATE Study	23-07-31	CI
EXACT Therapeutics AS Announces Management Changes	23-06-09	CI
EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21	CI
EXACT THERAPEUTICS AS Presents Encouraging Clinical Case Report Data At Science & Technology Event	23-03-27	CI
Exact Therapeutics Gets UK Clearance to Reopen Phase 1 Acoustic Cluster Therapy Trial	23-02-02	MT
Exact Therapeutics Receives Regulatory Approval to Reopen the Activate Clinical Trial	23-02-02	CI
Norway's Exact Therapeutics Wins NOK16 Million Grant for Cancer Therapy Research; Shares Tumble 24%	22-12-22	MT
Norwegian Research Council Awards EXACT Therapeutics AS Exact-Tx NOK 16 Million to Support the Research of Immunotherapy Responses in Solid Tumours with Acoustic Cluster Therapy	22-12-22	CI
EXACT Therapeutics AS And Tgen Publish Preclinical Data On Acoustic Cluster Therapy Combined With Chemotherapy In A Pancreatic Cancer Model	22-11-22	CI
EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-21	CI
EXACT Therapeutics Appoints Chief Medical Officer	22-09-16	MT
EXACT Therapeutics AS Announces Appointment of Amir Snapir as Chief Medical Officer, Effective 21 September 2022	22-09-15	CI
Norway's Exact Therapeutics Appoints New CFO	22-08-31	MT
EXACT Therapeutics AS Appoints John Edminson as Chief Financial Officer, Effective 1 October 2022	22-08-30	CI
Exact Therapeutics, GE Secure $1.6 Million Norwegian Grant for Ultrasound Imaging, Therapy Project	22-06-23	MT

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Sector

Biotechnology & Medical Research

Calendar

2024-06-06 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EXACT THERAPEUTICS	-43.33%	19.85M
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B